Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2014

01-03-2014 | Original Article

Anxiety, depression, and quality of life in German ambulatory breast cancer patients

Authors: Hendrikje Schleife, Christine Sachtleben, Carolyn Finck Barboza, Susanne Singer, Andreas Hinz

Published in: Breast Cancer | Issue 2/2014

Login to get access

Abstract

Background

The aim of the study was to determine the predictors of health-related quality of life in ambulatory breast cancer patients.

Methods

A total of 107 breast cancer outpatients were tested with the Hospital Anxiety and Depression Scale (HADS) and the quality of life instrument EORTC QLQ-C30. Furthermore, the degree of social support and shared decision making (SDM) were assessed.

Results

In nearly all domains of EORTC QLQ-C30 the patients reported worse mean scores than the general population in a clinically significant range, especially in the symptom scales. Therapy-related factors and the degree of SDM contributed only marginally to quality of life. Social support, however, proved to be predictive of better mental health and better quality of life in many domains.

Conclusion

Irrespective of the therapy, the social network of the patients should be activated to help the patients to cope with the disease. However, the findings do not support the idea that enhanced SDM would have beneficial effects on mental health.
Literature
1.
Singer S, Das-Munshi J, Brähler E. Prevalence of mental health conditions in cancer patients in acute care—a meta-analysis. Ann Oncol. 2010;21:925–30.PubMedCrossRef
2.
Kramer JA, Curran D, Piccart M, De Haes JCJM, Bruning P, Klijn J, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer. 2000;36:1498–506.PubMedCrossRef
3.
Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Holzel D. Predictors of quality of life of breast cancer patients. Acta Oncol. 2003;42:710–8.PubMedCrossRef
4.
Waldmann A, Pritzkuleit R, Raspe H, Katalinic A. The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein. Qual Life Res. 2007;16:767–76.PubMedCrossRef
5.
Arndt V, Merx H, Sturmer T, Stegmaier C, Ziegler H, Brenner H. Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer. 2004;40:673–80.PubMedCrossRef
6.
Schou I, Ekeberg O, Sandvik L, Hjermstad MJ, Ruland CM. Multiple predictors of health-related quality of life in early stage breast cancer. Data from a year follow-up study compared with the general population. Qual Life Res. 2005;14:1813–23.PubMedCrossRef
7.
Groenvold M, Fayers PM, Sprangers MAG, Bjorner JB, Klee MC, Aaronson NK, et al. Anxiety and depression in breast cancer patients at low risk of recurrence compared with the general population: a valid comparison? J Clin Epidemiol. 1999;52:523–30.PubMedCrossRef
8.
Schwarz R, Krauss O, Hoeckel M, Meyer A, Zenger M, Hinz A. The course of anxiety and depression in patients with breast cancer and gynaecological cancer. Breast Care. 2008;3:417–22.PubMedCentralPubMedCrossRef
9.
Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32.
10.
Kornblith AB, Herndon JE, Zuckerman E, Viscoli CM, Horwitz RI, Cooper MR, et al. Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer. 2001;91:443–54.PubMedCrossRef
11.
Manning-Walsh J. Social support as a mediator between symptom distress and quality of life in women with breast cancer. JOGNN J Obst Gyn Neo. 2005;34:482–93.CrossRef
12.
Kraetschmer N, Sharpe N, Urowitz S, Deber RB. How does trust affect patient preferences for participation in decision-making? Health Expect. 2004;7:317–26.PubMedCrossRef
13.
O’Brien MA, Whelan TJ, Charles C, Ellis PM, Gafni A, Lovrics P, et al. Women’s perceptions of their treatment decision-making about breast cancer treatment. Patient Educ Couns. 2008;73:431–6.PubMedCrossRef
14.
Hinz A, Schwarz R. Anxiety and depression in the general population. A standardization study of the Hospital Anxiety and Depression Scale (in German with English abstract). Psychother Psychosom Med Psychol. 2001;51:193–200.PubMedCrossRef
15.
Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37:1345–51.PubMedCrossRef
16.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70.PubMedCrossRef
17.
Singer S, Kuhnt S, Götze H, Hauss J, Hinz A, Liebmann A, et al. Hospital Anxiety and Depression Scale cut-off scores for cancer patients in acute care. Br J Cancer. 2009;100:908–12.PubMedCentralPubMedCrossRef
18.
Hinz A, Krauss O, Hauss JP, Hockel M, Kortmann RD, Stolzenburg JU, et al. Anxiety and depression in cancer patients compared with the general population. Eur J Cancer Care. 2010;19:522–9.CrossRef
19.
Brennan C, Worrall-Davies A, McMillan D, Gilbody S, House A. The Hospital Anxiety and Depression Scale: a diagnostic meta-analysis of case-finding ability. J Psychosom Res. 2010;69:371–8.PubMedCrossRef
20.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.PubMedCrossRef
21.
Groenvold M, Klee MC, Sprangers MAG, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;50:441–50.PubMedCrossRef
22.
Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Cancer. 1999;35:1565–70.PubMedCrossRef
23.
Ogce F, Ozkan S, Baltalarli B. Psychosocial stressors, social support and socio-demographic variables as determinants of quality of life of Turkish breast cancer patients. Asian Pac J Cancer Prev. 2007;8:77–82.PubMed
24.
25.
Vaglio J Jr, Conard M, Poston WS, O’Keefe J, Haddock CK, House J, et al. Testing the performance of the ENRICHD Social Support Instrument in cardiac patients. Health Qual Life Outcomes. 2004;2:24.
Metadata
Title
Anxiety, depression, and quality of life in German ambulatory breast cancer patients
Authors
Hendrikje Schleife
Christine Sachtleben
Carolyn Finck Barboza
Susanne Singer
Andreas Hinz
Publication date
01-03-2014
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0378-6

Other articles of this Issue 2/2014

Breast Cancer 2/2014 Go to the issue

Original Article

Diagnostic and therapeutic value of ductoscopy in nipple discharge and intraductal proliferations compared with standard methods

Author's Reply

In reply: Maspin and it’s evolving role in tumor progression in systemic malignancies

Original Article

Feasibility of prior administration of cyclophosphamide in TC combination treatment

Letter to the Editor

Maspin and it’s evolving role in tumor progression in systemic malignancies

Original Article

Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone

Original Article

Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits